CK Immunohistochemistry Testing Services at Lahore PCR Lab

CK Immunohistochemistry at Lahore PCR Lab

CK Immunohistochemistry, or Cytokeratin Immunohistochemistry (IHC), is an advanced diagnostic laboratory technique performed at Lahore PCR Lab in Lahore, Pakistan. This specialized pathological evaluation is designed to detect specific cytokeratin proteins within tissue specimens. Cytokeratins are intermediate filament proteins found in the intracytoplasmic cytoskeleton of epithelial cells. Because different types of epithelial cells express distinct subsets of cytokeratins, analyzing these proteins provides critical diagnostic insights. This test is of paramount clinical importance in oncology, surgical pathology, and personalized medicine, helping pathologists and oncologists accurately classify tumors, determine their tissue of origin, and formulate targeted treatment strategies.

At Lahore PCR Lab, the CK Immunohistochemistry test is performed using state-of-the-art automated staining platforms and high-affinity antibodies. This ensures maximum sensitivity and specificity, minimizing the risk of false-positive or false-negative results. The diagnostic value of this test lies in its ability to differentiate between various types of cancers that may look identical under a standard hematoxylin and eosin (H&E) stain. For instance, highly undifferentiated tumors often lose their characteristic microscopic features, making it difficult to determine whether they are carcinomas, sarcomas, melanomas, or lymphomas. By identifying the presence and specific pattern of cytokeratins, CK Immunohistochemistry provides a definitive lineage assessment. This level of diagnostic precision is essential for selecting the most effective chemotherapy regimens, immunotherapies, or surgical interventions, ultimately improving patient outcomes and survival rates.

The anatomical structures evaluated during a CK Immunohistochemistry test depend entirely on the site of the biopsy or surgical resection. Common specimens include tissues from the lung, breast, colon, prostate, liver, lymph nodes, and soft tissues. The primary benefit of undergoing this analysis at Lahore PCR Lab is the assurance of receiving a highly accurate, peer-reviewed pathology report. Our laboratory utilizes rigorous quality control measures, ensuring that every tissue section is processed, stained, and interpreted according to international diagnostic standards. This test is commonly indicated for patients with newly diagnosed tumors, metastatic cancers of unknown primary origin, or complex lesions requiring differentiation between benign and malignant conditions.

Clinical Procedure: What to Expect

Patient Preparation

Because CK Immunohistochemistry is performed on tissue samples that have already been extracted from the patient, direct patient preparation is minimal. However, ensuring the proper handling and submission of the tissue specimen is critical for accurate results. Patients and referring physicians should observe the following guidelines:

• Submit the Correct Specimen: Provide the formalin-fixed paraffin-embedded (FFPE) tissue block (commonly referred to as the biopsy block) along with the corresponding hematoxylin and eosin (H&E) stained slides.
• Provide Clinical History: Always include a detailed clinical history, previous pathology reports, imaging results, and the primary clinical suspicion. This information helps the consultant pathologist interpret the staining patterns in the correct clinical context.
• Ensure Proper Fixation: If the biopsy is performed at an external facility, ensure the tissue was fixed in 10% neutral buffered formalin within the recommended time frame (typically 6 to 48 hours) to preserve antigenicity.
• No Fasting Required: Since the test is performed on an existing tissue sample, there are no dietary restrictions, fasting requirements, or medication adjustments needed for the patient.

During the Procedure

The laboratory procedure for CK Immunohistochemistry at Lahore PCR Lab involves several highly technical steps executed by experienced histotechnologists and evaluated by consultant pathologists:

• Tissue Sectioning: The submitted paraffin block is mounted on a microtome, and extremely thin sections (typically 3 to 4 micrometers thick) are cut and placed onto specialized charged glass slides.
• Deparaffinization and Rehydration: The slides are heated and treated with solvents like xylene and descending grades of alcohol to remove the paraffin wax and rehydrate the tissue sections.
• Antigen Retrieval: The tissue is subjected to heat-induced epitope retrieval (HIER) or enzymatic digestion. This step breaks the protein cross-links formed during formalin fixation, exposing the target cytokeratin antigens to the antibodies.
• Antibody Incubation: The tissue sections are incubated with primary antibodies specific to the cytokeratins being tested (e.g., CK7, CK20, CK5/6, CK19, or Pan-CK). After washing, secondary antibodies conjugated with detection enzymes are applied.
• Chromogen Visualization: A chromogen substrate (usually diaminobenzidine or DAB) is applied, which reacts with the enzymes to produce a visible brown precipitate at the site of antibody-antigen binding.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to visualize cellular nuclei, dehydrated, and sealed with a coverslip.
• Microscopic Evaluation: A consultant pathologist examines the slides under a high-resolution light microscope to assess the intensity, distribution, and intracellular localization (cytoplasmic or membranous) of the staining.

When is a CK Immunohistochemistry Performed?

Differentiating Carcinoma from Sarcoma

One of the most frequent indications for CK Immunohistochemistry is distinguishing between carcinomas and sarcomas. Carcinomas originate from epithelial cells and are almost universally positive for cytokeratins. In contrast, sarcomas originate from mesenchymal cells and are generally negative for cytokeratins. When a patient presents with a highly undifferentiated, aggressive mass, standard microscopic examination may not reveal its cellular origin. By performing a Pan-Cytokeratin stain, the pathologist can confidently classify the tumor as epithelial (carcinoma) or mesenchymal (sarcoma), which is a critical distinction because the treatment protocols for these two classes of cancer are vastly different.

Identifying the Primary Site of Metastatic Cancer

When a patient is diagnosed with metastatic cancer—where the cancer has spread to distant organs like the liver, lungs, or bones—it is crucial to identify where the cancer started (the primary site). CK Immunohistochemistry is highly effective for this purpose, particularly through the combined use of Cytokeratin 7 (CK7) and Cytokeratin 20 (CK20). Different organs have characteristic CK7 and CK20 expression profiles. For example, a CK7-positive and CK20-negative profile strongly suggests a primary tumor in the lung, breast, or thyroid, while a CK7-negative and CK20-positive profile is highly characteristic of colorectal cancer. Identifying the primary site allows oncologists to prescribe tumor-specific therapies rather than empirical treatments.

Subtyping Epithelial Tumors

Even within carcinomas, subtyping is essential for guiding therapy. CK Immunohistochemistry helps differentiate between various subtypes of epithelial malignancies. For instance, in lung cancer, distinguishing between adenocarcinoma and squamous cell carcinoma is vital because certain targeted therapies and immunotherapies are only effective against specific subtypes. Pathologists use specific cytokeratins, such as CK5/6 (which highlights squamous differentiation) and CK7 (which highlights glandular differentiation), to accurately subtype these tumors, ensuring that patients receive the most appropriate and safe therapeutic agents.

Evaluating Undifferentiated Malignancies

Undifferentiated or anaplastic malignancies are tumors that have lost all morphological resemblance to their tissue of origin. These tumors pose a significant diagnostic challenge because they lack the structural features (such as gland formation or keratin pearls) that pathologists use for visual identification. In such cases, physicians request a comprehensive immunohistochemical panel that includes CK markers. Detecting cytokeratin expression in these highly abnormal cells confirms an epithelial lineage, preventing misdiagnosis and ensuring that the patient is directed to the correct oncological specialty for management.

Distinguishing In Situ vs. Invasive Carcinoma

CK Immunohistochemistry is also utilized to differentiate between in situ (non-invasive) and invasive carcinomas, particularly in breast and prostate pathology. In the breast, distinguishing ductal carcinoma in situ (DCIS) from invasive ductal carcinoma (IDC) is critical. Pathologists use antibodies against high molecular weight cytokeratins (such as CK5/6 or 34betaE12) to highlight the presence of an intact myoepithelial/basal cell layer around the ducts. The loss of this cytokeratin-positive basal layer indicates that the tumor cells have breached the basement membrane and become invasive, which significantly alters the surgical and systemic treatment approach.

What Does a CK Immunohistochemistry Detect?

CK Immunohistochemistry detects the presence, concentration, and spatial distribution of specific cytokeratin intermediate filaments within tissue cells. The clinical findings from this test are highly specific and provide a molecular map of the tumor. Here are the key findings that this diagnostic test can detect:

• Diffuse Pan-Cytokeratin Positivity: Confirms the epithelial origin of the tumor, establishing a diagnosis of carcinoma.
• Pan-Cytokeratin Negativity: Suggests a non-epithelial lineage, pointing toward melanoma, lymphoma, sarcoma, or neuroendocrine tumors.
• CK7 Positive / CK20 Negative Profile: Strongly associated with primary adenocarcinomas of the lung, breast, thyroid, ovary, and endometrium.
• CK7 Negative / CK20 Positive Profile: Highly specific for colorectal adenocarcinoma and Merkel cell carcinoma.
• CK7 Positive / CK20 Positive Profile: Commonly observed in urothelial (bladder) carcinomas, pancreatic adenocarcinomas, and gastric cancers.
• CK7 Negative / CK20 Negative Profile: Typically seen in hepatocellular carcinoma, renal cell carcinoma, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.
• CK5/6 Positivity: Indicates squamous cell differentiation or mesothelioma, helping differentiate mesothelioma from lung adenocarcinoma.
• CK19 Positivity: Highly expressed in papillary thyroid carcinoma, cholangiocarcinoma, and breast carcinomas.
• High Molecular Weight Cytokeratin (34betaE12) Expression: Highlights basal cells in prostate tissue; its absence in atypical glands confirms prostate adenocarcinoma.
• CK14 Positivity: Detects myoepithelial cells in breast and salivary gland lesions, aiding in the evaluation of benign versus malignant breast conditions.
• CK8/18 Co-expression: Detected in most simple, non-stratified epithelia and their derived adenocarcinomas.
• CK17 Positivity: Associated with squamous cell carcinomas and specific glandular tumors, often serving as a prognostic marker.
• Perinuclear Dot-like CK20 Staining: A classic diagnostic hallmark of Merkel cell carcinoma, a rare and aggressive skin cancer.
• Focal Cytokeratin Positivity in Spindle Cell Tumors: Helps identify sarcomatoid carcinoma, a rare variant of carcinoma that mimics sarcoma.
• CK7 Positivity in Paget’s Disease: Confirms the presence of malignant Paget cells in the epidermis of the nipple or vulva.
• CK5/6 Negativity in Adenocarcinoma: Rules out squamous differentiation in poorly differentiated lung tumors.
• CK19 Positivity in Hepatic Lesions: Helps differentiate cholangiocarcinoma (positive) from hepatocellular carcinoma (usually negative).
• CK20 Positivity in Gastric Intestinal Metaplasia: Detects early pre-neoplastic changes in the gastric mucosa.
• CK14 Expression in Basal-like Breast Cancer: Identifies a specific, aggressive subtype of breast cancer associated with a poorer prognosis.
• Intact Basal Layer Cytokeratin Expression: Confirms benign prostatic hyperplasia or breast ductal carcinoma in situ (DCIS) without invasion.
• Loss of Basal Layer Cytokeratin Expression: Confirms invasive prostatic adenocarcinoma or invasive ductal carcinoma of the breast.
• Aberrant Cytokeratin Expression in Epithelioid Sarcoma: Detects cytokeratin positivity in a specific subtype of sarcoma, preventing diagnostic confusion.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that waiting for pathology results can be an anxious time for patients and their families. Because CK Immunohistochemistry is a highly specialized, multi-step molecular technique, it requires meticulous processing to ensure absolute accuracy. The turnaround time for IHC testing typically ranges from 3 to 5 working days. This timeframe allows our histotechnologists to perform high-precision staining and permits our consultant pathologists to thoroughly review the slides, compare them with standard controls, and correlate the findings with the patient’s clinical history.

Once the pathology report is finalized and signed off by our consultant pathologist, it is immediately uploaded to our secure online portal. Patients and referring physicians can access, view, and download the digital reports from the comfort of their homes via the Lahore PCR Lab website or mobile application. Additionally, physical copies of the reports can be collected directly from our main diagnostic center in Lahore. We also offer SMS notifications to inform patients the moment their reports are ready, ensuring a seamless and transparent diagnostic experience.

CK Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Pan-Cytokeratin (Pan-CK)	Positive in normal epithelial tissues	Positive in carcinomas; Negative in sarcomas, lymphomas, and melanomas
Cytokeratin 7 (CK7)	Positive in normal lung, breast, and gynecological epithelia	Strongly positive in lung adenocarcinoma and breast carcinoma; Negative in colon cancer
Cytokeratin 20 (CK20)	Positive in normal gastrointestinal and urothelium	Strongly positive in colorectal adenocarcinoma and Merkel cell carcinoma
Cytokeratin 5/6 (CK5/6)	Positive in basal cells of squamous epithelium and mesothelium	Positive in squamous cell carcinoma and mesothelioma; Negative in adenocarcinoma
Cytokeratin 19 (CK19)	Positive in normal simple epithelia and bile ducts	Overexpressed in papillary thyroid carcinoma and cholangiocarcinoma
High Molecular Weight CK (34betaE12)	Intact positive staining in basal cell layers of prostate and breast	Complete loss of staining in invasive prostate adenocarcinoma and invasive breast carcinoma
Cytokeratin 14 (CK14)	Positive in normal myoepithelial cells	Positive in basal-like breast cancers and squamous cell carcinomas

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for CK Immunohistochemistry?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists and skilled histotechnologists specializing in advanced oncopathology.
• Patient-Focused Care: We prioritize patient comfort and convenience, offering clear guidance throughout the sample submission and reporting process.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international quality control standards, ensuring the highest level of diagnostic accuracy.
• Professional Reporting: Our reports are comprehensive, detailed, and structured to provide oncologists with all the necessary molecular details for treatment planning.
• Modern Diagnostic Approach: We utilize state-of-the-art automated staining systems and premium-grade antibodies to minimize human error and variability.
• Comfortable Environment: Our main facility in Lahore provides a professional, clean, and welcoming environment for patients submitting samples.
• Convenient Location: Located centrally in Lahore, our laboratory is easily accessible to patients and hospitals across the city.
• Commitment to Accurate Diagnosis: We are dedicated to delivering precise, evidence-based results that physicians can trust for critical clinical decision-making.